FindTrial
Sign In

To see if Remdesivir, an antiviral drug helped in reducing the hospital stay and helped patients with COVID 19infection recover faster?

To study the clinical outcomes in hospitalized patients, receiving Remdesivir for moderate/severe COVID 19 infection, during August 2020 to October 2020 in a designated COVID hospital.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/04/032904
Enrollment
150
Registered
2021-04-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: J128- Other viral pneumonia

Interventions

None listed

Sponsors

Dr Punam Bhende
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: .

Exclusion criteria

Exclusion criteria: Not Applicable

Design outcomes

Primary

MeasureTime frame
Death, Discharge, Length of stay in hospital, duration of O2therapyTimepoint: 3 months—

Secondary

MeasureTime frame
the results will help in decision making and add to existing treatment protocolsTimepoint: 3 months—

Countries

India

Contacts

Public ContactDr Punam Bhende

H M Centre for Medical Care and Research

punamvb@charutarhealth.org9480703214

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026